# **AUSTRALIAN PRODUCT INFORMATION**

# **TACIDINE<sup>®</sup>**

(nizatidine) capsule

# 1 NAME OF THE MEDICINE

Nizatidine

# 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

TACIDINE capsules contain 150 mg or 300 mg of nizatidine as the active ingredient.

Excipients with known effect: phenylalanine.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

# **3 PHARMACEUTICAL FORM**

TACIDINE 150 capsules – hard gelatin capsule with a pale yellow body and dark yellow cap. The body has "NZ 150" and the cap has "G" printed in black.

TACIDINE 300 capsules – hard gelatin capsule with a light brown body and cap. The body has "NZ 300" and the cap has "G" printed in black.

# 4 CLINICAL PARTICULARS

### 4.1 THERAPEUTIC INDICATIONS

TACIDINE is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.

TACIDINE is also indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg at bedtime, after healing of the active duodenal ulcer. Continuous therapy with nizatidine for longer than 1 year has not been studied.

TACIDINE is indicated for up to 8 weeks for the treatment of benign gastric ulcer.

TACIDINE is indicated for up to 12 weeks for the treatment of oesophagitis, including erosive and ulcerative oesophagitis and associated heartburn due to reflux.

### 4.2 DOSE AND METHOD OF ADMINISTRATION

### Active Duodenal Ulcer

The recommended oral dosage for adults is 150 mg twice daily or 300 mg once daily in the evening (for up to 8 weeks). In most cases, the ulcer will heal within 4 weeks.

### **Benign Gastric Ulcer**

The recommended daily dose is 150 mg twice daily or 300 mg once daily in the evening (for up to 8 weeks). Prior to treatment with nizatidine, care should be taken to exclude the possibility of gastric cancer.

### **Maintenance Therapy**

The recommended oral dosage for adults with duodenal ulcer is 150 mg once daily in the evening for a period not exceeding 12 months. Continuous therapy with nizatidine for longer than 12 months has not been studied.



#### Gastro-oesophageal Reflux Disease

The recommended oral dosage in adults for the treatment of erosions, ulcerations, and associated heartburn is 150 mg twice daily (for up to 12 weeks).

#### Dosage Adjustment for Patients with Moderate to Severe Renal Insufficiency

The dose for patients with renal dysfunction should be reduced as follows:

Creatinine Clearance	Dose
20 to 50 mL/min	150 mg daily
< 20 mL/min	150 mg every 2 days
Maintenance Therapy (Duodenal Ulcer)	
20 to 50 mL/min	150 mg every 2 days
< 20 mL/min	150 mg every 3 days

Some elderly patients may have creatinine clearances of less than 50 mL/min, and based on pharmacokinetic data in patients with renal impairment, the dose for such patients should be reduced accordingly. The clinical effects of this dosage reduction in patients with renal failure have not been evaluated.

#### 4.3 CONTRAINDICATIONS

Nizatidine is contraindicated in patients with known hypersensitivity to the drug or excipients, and because cross sensitivity in this class of compounds has been observed, nizatidine should not be administered to patients with a history of hyper-sensitivity to other H2-receptor antagonists.

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

#### **Gastric Malignancy**

Symptomatic response to nizatidine therapy does not preclude the presence of gastric malignancy. Prior to treatment, care should be taken to exclude the possibility of malignant gastric ulceration.

#### **Nosocomial Pulmonary Infections**

There is a possibility of nosocomial pulmonary infections associated with bacterial colonisation of the stomach in patients in Intensive Care Units receiving drugs which suppress acid secretion.

#### Use in Hepatic Impairment

Pharmacokinetic studies in patients with hepato-renal syndrome have not been done. Part of the dose of nizatidine is metabolised in the liver. Nizatidine cannot be recommended in patients with hepatic failure. In patients with normal renal function and uncomplicated hepatic dysfunction, the disposition of nizatidine is similar to that in normal subjects.

#### **Use in Renal Impairment**

Because nizatidine is excreted primarily by the kidney, dosage should be reduced in patients with moderate to severe renal insufficiency (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

#### Use in the Elderly

Ulcer healing rates in elderly patients are similar to those in younger age groups. The incidence rates of adverse events and laboratory test abnormalities are also similar to those seen in other age groups. Age alone may not be an important factor in the disposition of nizatidine. Nizatidine is known to be substantially excreted by the kidney, and the toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have reduced renal function. Care should be taken in the dose selection in this patient group and may be useful to monitor renal function (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of histamine H2-receptor antagonists versus those that had stopped treatment, with an observed adjusted relative risk of 1.63 (95% Cl, 1.07-2.48).

#### **Paediatric Use**

Safety and effectiveness in children have not been established.

#### **Effects on Laboratory Tests**

False-positive tests for urobilinogen with Multistix may occur during therapy with nizatidine.

# 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, warfarin, aminophylline, diazepam, and metoprolol. Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolising enzyme system; therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. However, nizatidine and other histamine H2-receptor antagonists can reduce the gastric absorption of drugs whose absorption is dependent on an acidic gastric pH. In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg twice daily, was administered concurrently.

#### Endocrine and Metabolism

The prolonged use of H2-receptor antagonists may impair the absorption of protein-bound Vitamin B12 and may contribute to the development of cyanocobalamin (vitamin B12) deficiency.

#### 4.6 FERTILITY, PREGNANCY AND LACTATION

#### **Effects on Fertility**

In a 2-generation, perinatal and postnatal, fertility study in rats, doses of nizatidine up to 650 mg/kg/day produced no adverse effects on the reproductive performance of parental animals or their progeny.

#### **Use in Pregnancy**

Pregnancy category: B3

Oral reproduction studies in rats at doses up to 1500 mg/kg, and in Dutch Belted rabbits at doses up to 275 mg/kg, revealed no evidence of impaired fertility or teratogenic-effect. At doses above 275 mg/kg treated rabbits had abortions, decreased number of live fetuses, and depressed fetal weights. On intravenous administration to pregnant New Zealand white rabbits, nizatidine at 20 mg/kg produced cardiac enlargement, coarctation of the aortic arch, and cutaneous oedema in 1 fetus and at 50 mg/kg it produced ventricular anomaly, distended abdomen, spina bifida, hydrocephaly, and enlarged heart in 1 fetus.

There are, however, no adequate and well-controlled studies in pregnant women. It is also not known whether nizatidine can cause fetal harm when administered to pregnant women or can affect reproduction capacity.

Nizatidine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### **Use in Lactation**

Studies conducted in lactating women have shown that 0.1% of the administered oral dose of nizatidine is secreted in human milk in proportion to plasma concentrations. Because of the growth depression in pups reared by lactating rats treated with nizatidine, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

### 4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

### 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Nizatidine has been shown to be generally well tolerated. The safety profile is at least as good, if not better than, other H2-receptor antagonists.

Worldwide, controlled clinical trials of nizatidine included over 6,000 patients given nizatidine in studies of varying durations. Placebo-controlled trials included over 2,600 patients given nizatidine and over 1,700 given placebo. Among the adverse events in the placebo-controlled trials, anaemia (0.2% vs 0%) and urticaria (0.5% vs 0.1%) were significantly more common in the nizatidine group.

#### <u>Hepatic</u>

Hepatocellular injury, evidenced by elevated liver enzyme tests (SGOT [AST], SGPT [ALT], or alkaline phosphatase), occurred in some patients and was possibly or probably related to nizatidine. In some cases there was marked elevation of SGOT, SGPT enzymes (greater than 500 IU/L) and in a single instance SGPT was greater than 2,000 IU/L. The overall rate of occurrences of elevated liver enzymes and elevations to 3 times the upper limit of normal, however, did not significantly differ from the rate of liver enzyme abnormalities in placebo treated patients. All abnormalities were reversible after discontinuation of nizatidine.

Rare cases of hepatitis and jaundice and cholestatic or mixed hepato-cellular and cholestatic injury with jaundice have been reported with reversal of the abnormalities after discontinuation of nizatidine.

#### Cardiovascular

In clinical pharmacology studies, short episodes of asymptomatic ventricular tachycardia occurred in 2 individuals administered nizatidine and in 3 untreated subjects.

#### <u>CNS</u>

Rare cases of reversible mental confusion have been reported.

#### **Endocrine**

Clinical pharmacology studies and controlled clinical trials showed no evidence of anti-androgenic activity due to nizatidine. Impotence and decreased libido were reported with equal frequency by patients who received nizatidine and by those given placebo. Rare reports of gynaecomastia occurred.

#### <u>Haematologic</u>

Anaemia was reported significantly more frequently in nizatidine (0.2%) than in placebo-treated (0%) patients. Fatal thrombocytopenia was reported in a patient who was treated with nizatidine and another H2 receptor antagonist. On previous occasions, this patient had experienced thrombocytopenia while taking other drugs. Rare cases of thrombocytopenic purpura, leucopenia, agranulocytosis, anaemia have been reported.

#### **Integumental**

Sweating and urticaria were reported significantly more frequently in nizatidine than in placebo patients. Rash, exfoliative dermatitis and pruritis were also reported.

#### **Hypersensitivity**

As with other H2-receptor antagonists, rare cases of anaphylaxis following administration of nizatidine have been reported. Rare episodes of hypersensitivity reactions (e.g. bronchospasm, laryngeal oedema, rash, and eosinophilia) have been reported.

#### Body as a Whole

Serum sickness reactions have occurred rarely (in less than 1/1,000 patients) in conjunction with nizatidine use.

#### Genitourinary

Reports of impotence have occurred.

#### Other

Hyperuricaemia not associated with gout or nephrolithiasis has been reported. Eosinophilia, fever and nausea related to nizatidine administration have been reported.

Other reported adverse effects include somnolence, vasculitis, arthralgia, myalgia, headache, pain (including abdominal, chest and back pain), asthenia, diarrhoea, flatulence, vomiting, dyspepsia, constipation, dry mouth, tooth disorder, dizziness, insomnia, abnormal dreams, anxiety, nervousness, rhinitis, pharyngitis, sinusitis, increased cough and amblyopia.

#### **Reporting Suspected Adverse Effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

### 4.9 OVERDOSE

Overdoses with nizatidine have been reported rarely. The following is provided to serve as a guide should such an overdose be encountered.

#### Signs and Symptoms

There is little clinical experience with overdosage of nizatidine in humans. Test animals that received large doses of nizatidine have exhibited cholinergic-type effects, including lacrimation, salivation, emesis, miosis, and diarrhoea. Single oral doses of 800 mg/kg in dogs and of 1,200 mg/kg in monkeys were not lethal. Intravenous median lethal doses in the rat and mouse were 301 mg/kg and 232 mg/kg respectively.

#### Treatment

In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

If overdosage occurs, use of activated charcoal should be considered along with clinical monitoring and supportive therapy. Renal dialysis for 4 to 6 hours increased plasma clearance.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

### 5 PHARMACOLOGICAL PROPERTIES

### 5.1 PHARMACODYNAMIC PROPERTIES

#### **Mechanism of Action**

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells.

#### Antisecretory Activity

Effects on Acid Secretion

#### TACIDINE® - PRODUCT INFORMATION

Nizatidine significantly inhibits basal and nocturnal gastric-acid secretion for up to 12 hours. Nizatidine also significantly inhibits gastric-acid secretion stimulated by food, caffeine, betazole, and pentagastrin in a dose dependent manner. Rebound hypersecretion of gastric acid may occur after cessation of the drug.

#### Effects on Other Gastrointestinal Secretions – Pepsin

Oral administration of 75 to 300 mg of nizatidine does not affect pepsin activity in gastric secretions. Total pepsin output is reduced in proportion to the reduced volume of gastric secretions.

#### Intrinsic Factor

Intrinsic factor is not decreased in subjects administered nizatidine.

#### Serum Gastrin

Nizatidine has no effect on basal serum gastrin. No rebound of gastrin secretion was observed when food was ingested 12 hours after administration of nizatidine.

#### Other Pharmacologic Actions

#### Hormones

Nizatidine was not shown to affect the serum concentrations of gonadotropins, growth hormone, antidiuretic hormone, cortisol, tri-iodothyronine, levothyroxine, testosterone,  $5\alpha$ -dihydrotestosterone, androstenedione, or estradiol. With acute nizatidine administration, transient increases in serum prolactin have been observed in male animals.

Nizatidine had no demonstrable anti-androgenic action.

#### **Clinical Trials**

#### Active Duodenal Ulcer

In multicentre, double-blind, placebo-controlled studies, endoscopically diagnosed duodenal ulcers healed more rapidly following administration of nizatidine, 300 mg at bedtime or 150 mg twice daily, than with placebo. Lower doses, such as 100 mg at bedtime, had slightly lower effectiveness.

#### Maintenance of Healed Duodenal Ulcer

In multicentre, double-blind, comparator-controlled studies, the healing rates following the administration of nizatidine (N = 388) were 81% within 4 weeks and 92% within 8 weeks.

Treatment with a reduced dose of nizatidine has been shown to be effective as maintenance therapy following healing of active duodenal ulcers. In multicentre, double-blind, placebo-controlled studies, 150 mg of nizatidine taken in the evening resulted in a significantly lower incidence of duodenal ulcer recurrence in patients treated for up to 1 year.

#### Benign Gastric Ulcer

In multicentre, double-blind, comparator-controlled studies, patients received nizatidine 150 mg twice daily or nizatidine 300 mg in the evening. Healing rates in both dosage groups (66.2% and 65.2%, respectively) were not statistically different. Analysis of symptomatic responses showed that 68-76% of patients were symptom free after 4 weeks therapy.

#### Gastro-oesophageal Reflux Disease (reflux oesophagitis)

In multicentre, double-blind, placebo-controlled clinical trials, nizatidine was more effective than placebo in improving endoscopically diagnosed oesophagitis and in healing erosive and ulcerative oesophagitis.

In a study in patients with erosive or ulcerative oesophagitis, nizatidine, 150 mg twice daily, compared with placebo, yielded a higher healing rate at 3 weeks (16% vs. 7%) and at 6 weeks (32% vs. 16%, p < 0.05). In

another study, nizatidine, 150 mg twice daily, compared to placebo treatment, showed a higher healing rate at 6 weeks (21% vs. 11%, p < 0.05) and at 12 weeks (29% vs. 13%, p < 0.01).

In addition, relief of associated heartburn was greater in patients treated with nizatidine. Patients treated with nizatidine consumed fewer antacids than did patients treated with placebo.

### 5.2 PHARMACOKINETIC PROPERTIES

#### Absorption

The onset is half an hour while the duration of action is up to 12 hours. The absolute oral bioavailability of nizatidine exceeds 70%.

The oral bioavailability of nizatidine is unaffected by concomitant ingestion of propantheline. Antacids consisting of aluminium and magnesium hydroxides with simethicone decrease the absorption of nizatidine by about 10%. With food the AUC and  $C_{max}$  increase by approximately 10%.

Charcoal has also been shown to reduce oral bioavailability of nizatidine. This reduction is in the range of 20 to 25%.

#### Distribution

Peak plasma concentrations (700 to 1,800 microgram/L for a 150 mg dose and 1,400 to 3,600 microgram/L for a 300 mg dose) occur from 0.5 to 3 hours following the dose. A concentration of 1,000 microgram/L is equivalent to 3 micromol/L; a dose of 300 mg is equivalent to 905 micromoles. Plasma concentrations 12 hours after administration are less than 10 microgram/L. The elimination half-life is 1 to 2 hours, plasma clearance is 40 to 60 L/h, and the volume of distribution is 0.8 to 1.5 L/kg. Because of the short half-life and rapid clearance of nizatidine, accumulation of the drug would not be expected in individuals with normal renal function who take either 300 mg once daily in the evening or 150 mg twice daily. Nizatidine exhibits dose proportionality over the recommended dose range.

Approximately 35% of nizatidine is bound to plasma protein, mainly to alpha 1-acid glycoprotein. Warfarin, diazepam, paracetamol, propantheline, phenobarbital, and propranolol did not affect plasma protein binding of nizatidine *in vitro*.

#### Metabolism

Less than 7% of an oral dose is metabolised as  $N_2$ -monodesmethyl-nizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the  $N_2$ -oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

#### Excretion

More than 90% of an oral dose of nizatidine is excreted in the urine within 12 hours. About 60% of an oral dose is excreted as unchanged drug. Renal clearance is about 500 mL/min, which indicates excretion by active tubular secretion. Less than 6% of an administered dose is eliminated in the faeces.

#### **Pharmacokinetics in Special Populations**

Moderate to severe renal impairment significantly prolongs the half-life and decreases the clearance of nizatidine. In individuals who are functionally anephric, the half-life is 3.5 to 11 hours, and the plasma clearance is 7 to 14 L/h. To avoid accumulation of the drug in individuals with clinically significant renal impairment, the amount and/or frequency of doses of nizatidine should be reduced in proportion to the severity of dysfunction (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

### 5.3 PRECLINICAL SAFETY DATA

### Genotoxicity

No data available.

#### Carcinogenicity

A two-year oral carcinogenicity study in rats with doses as high as 500 mg/kg/day (about 80 times the recommended daily therapeutic dose) showed no evidence of a carcinogenic effect. There was a dose related increase in the density of enterochromaffin-like (ECL) cells in the gastric oxyntic mucosa. In a two-year study in mice, there was no evidence of a carcinogenic effect in male mice; although hyperplastic nodules of the liver were increased in the high dose males as compared to placebo. Female mice given the high dose of nizatidine (2,000 mg/kg/day, about 330 times the human dose) showed marginally statistically significant increases in hepatic carcinoma and hepatic nodular hyperplasia with no numerical increase seen in any of the other dose groups. The rate of hepatic carcinoma in the high dose animals was within the historical control limits seen for the strain of mice used. The female mice were given a dose higher than the maximum tolerated dose, as indicated by excessive (30%) weight decrement as compared with concurrent controls, and evidence of mild liver injury (transaminase elevations). The occurrence of a marginal finding at high dose only in animals given an excessive, and somewhat hepatotoxic dose, with no evidence of a carcinogenic effect in rats, male mice, and female mice (given up to 360 mg/kg/day, about 60 times the human dose), and a negative mutagenicity battery are not considered evidence of a carcinogenic potential for nizatidine.

### Mutagenicity

Nizatidine was not mutagenic in a battery of tests performed to evaluate its potential genetic toxicity, including bacterial mutation tests, unscheduled DNA synthesis, sister chromatid exchange, mouse lymphoma assay, chromosome aberration tests, and a micronucleus test.

# 6 PHARMACEUTICAL PARTICULARS

### 6.1 LIST OF EXCIPIENTS

The capsules also contain the following inactive excipients: colloidal anhydrous silica, sodium lauryl sulfate, croscarmellose sodium, pregelatinised maize starch, purified talc, magnesium stearate, quinoline yellow (150 mg only), allura red AC (150 mg only), iron oxide yellow, iron oxide red (300 mg only), titanium dioxide, gelatin, TekPrint SW-9008 Black Ink (ID 2328) and TekPrint SW-9009 Black Ink (ID 2343).

### 6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

### 6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### 6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

### 6.5 NATURE AND CONTENTS OF CONTAINER

Container type: blister pack (PVC/Al)

Pack sizes: 30 or 60 capsules

Some strengths, pack sizes and/or pack types may not be marketed.

#### Australian Register of Therapeutic Goods (ARTG)

AUST R 94204 – TACIDINE nizatidine 150mg capsule blister pack

AUST R 94205 - TACIDINE nizatidine 300mg capsule blister pack


### 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

### 6.7 PHYSICOCHEMICAL PROPERTIES

#### **Chemical Structure**

Nizatidine is an off-white to buff crystalline solid that is sparingly soluble in water. Pharmacologically, it is a histamine, H2-receptor antagonist.



Chemical name: N-[2-[[[2-(dimethylamino)methyl]-4-thiazolyl]-methyl]thio]- ethyl]-N'-methyl-2-nitro-1,1- ethenediamine

Molecular formula: C12H21N5O2S2

Molecular weight: 331.46

#### **CAS Number**

76963-41-2

# 7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 (Prescription Only Medicine)

# 8 SPONSOR

#### Alphapharm Pty Ltd trading as Viatris

Level 1, 30 The Bond 30 – 34 Hickson Road Millers Point NSW 2000 www.viatris.com.au Phone: 1800 274 276

# 9 DATE OF FIRST APPROVAL

29/04/2003

### **10 DATE OF REVISION**

28/10/2024

#### **Summary Table of Changes**

Section Changed	Summary of New Information
All	Minor editorial changes
4.8	Additional adverse effects: leucopenia, agranulocytosis, anaemia

TACIDINE<sup>®</sup> is a Viatris company trade mark

### TACIDINE\_pi\Oct24/00